摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8R,9S,10R,13S,14S)-10,13-二甲基-7-(苯基甲基)-9,11,12,14,15,16-六氢-8H-环戊二烯并[a]菲-3,17-二酮 | 131802-66-9

中文名称
(8R,9S,10R,13S,14S)-10,13-二甲基-7-(苯基甲基)-9,11,12,14,15,16-六氢-8H-环戊二烯并[a]菲-3,17-二酮
中文别名
——
英文名称
7-Benzylandrosta-1,4,6-triene-3,17-dione
英文别名
(8R,9S,10R,13S,14S)-7-benzyl-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione
(8R,9S,10R,13S,14S)-10,13-二甲基-7-(苯基甲基)-9,11,12,14,15,16-六氢-8H-环戊二烯并[a]菲-3,17-二酮化学式
CAS
131802-66-9
化学式
C26H28O2
mdl
——
分子量
372.5
InChiKey
TZJKJQQPVWTQSG-AEFDYNLKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    28
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
    申请人:Wang Changjin
    公开号:US20100087402A1
    公开(公告)日:2010-04-08
    The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.
    本发明涉及治疗依赖雌激素的子宫过度增生性疾病,包括子宫内膜异位症、子宫肌瘤、子宫内膜增生、子宫癌及其相关症状,通过阴道给药至少两种活性药物,所选药物包括芳香化酶抑制剂、抗炎药和子宫选择性雌激素受体拮抗剂。这种联合疗法降低了局部雌激素产生,阻断了局部雌激素作用,并在局部抑制了炎症,导致对依赖雌激素的疾病组织的饥饿,缓解相关症状,延缓疾病进展。阴道给药最大限度地抑制了局部雌激素产生,而不显著影响全身循环雌激素水平。这导致增强的临床疗效和减少的副作用。
  • Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders
    申请人:Vivus, Inc.
    公开号:US20140080794A1
    公开(公告)日:2014-03-20
    The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.
查看更多